Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New VR device aims to make exercise fun for kids with muscle weakness

NCT ID NCT07578454

Symptom relief Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 16, 2026 · Updated 3 times

Summary

This early study tests a virtual reality rehabilitation device for children with spinal muscular atrophy (SMA), a genetic condition that causes progressive muscle weakness. The device uses games, muscle sensors, and a grip-strength ball to make home exercises more engaging. Researchers will ask 12 participants and their caregivers about how relevant and satisfying the device is, aiming to improve access to daily exercise.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VRehab SMA device (a virtual reality rehabilitation platform with EMG sensors and grip-strength ball)
What this could lead to
If it works, this could provide an engaging, at-home exercise tool for children with SMA, potentially improving motor function and quality of life.
What could go wrong
This is a very small, early proof-of-concept study with only 12 participants, so results may not apply broadly. The device is still being tested for relevance and usability, not yet for clinical effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cohort 1 Inclusion Criteria: * Person with SMA * A person living with genetically confirmed SMA aged from 12-18 years * A good understanding of English or someone who can provide a good understanding of English for me to complete the survey * A young person living with SMA from 12-15 years of age and who's caregiver/legal guardian gives consent * A young person living with SMA from 16-18 years of age who provide their own consent Caregiver/ Legal Guardian * A caregiver (legal guardian) of child/young person living with SMA aged from 6-18 years old * A good understanding of English or someone who can provide a good understanding of English for me to complete the survey Exclusion Criteria: No exclusion criteria for Cohort 1, other than meeting the inclusion criteria Cohort 2 Inclusion Criteria: Participant with SMA aged 6-10 years * Genetically confirmed SMA * A comprehensive understanding of English * Treated with any disease-modifying therapy post-symptomatically * Number of SMN2 copies available * Functional status available * Age: Participants between 6-10 years at Visit 1 (inclusion) * Parent(s)/legal guardian(s)/caregiver(s) able to provide written informed consent and child able to provide assent prior to participation in the study Participant with SMA aged 11-15 years * Genetically confirmed SMA * A comprehensive understanding of English * Treated with any disease-modifying therapy post-symptomatically * Number of SMN2 copies available * Functional status available * Age: Participants between 11-15 years at Visit 1 (inclusion) * Parent(s)/legal guardian(s)/caregiver(s) able to provide written informed consent and child able to provide assent prior to participation in the study Participant with SMA aged 16-18 years * Genetically confirmed SMA * A comprehensive understanding of English * Treated with any disease-modifying therapy post-symptomatically * Number of SMN2 copies available * Functional status available * Age: Participants between 16-18 years at Visit 1 (inclusion) * Able to provide written informed consent Exclusion Criteria: Any acute or chronic condition which, according to the investigator, significantly interferes with the use of the device (example: Upper limbs injuries interfering with technology, skin conditions preventing the use of electrodes, etc)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spinal muscular atrophy (SMA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

spinal muscular atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spinal muscular atrophy (SMA)

Contacts and locations

Locations

  • Oxford University

    Oxford, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.